top of page
Publications banner new.png
Small-orange-line

CYTORA's Technology-related Publications 

Marynka-Kalmani K, Treves S, Yafee M, et al. Stem Cells. 2010 May;28(5):984-95. doi: 10.1002/stem.425.PMID: 20474080

Ganz J, Arie I, Buch S, et al. PLoS One. 2014 Jun 19;9(6):e100445. doi: 10.1371/journal.pone.0100445. eCollection 2014.PMID: 24945922

Lopez-Letayf S, Arie I, Araidy S, et al. J Periodontal Res. 2022 Apr;57(2):305-315. doi: 10.1111/jre.12960. Epub 2021 Nov 28.PMID: 34839539

Treves-Manusevitz S, Hoz L, Rachima H, et al. J Clin Periodontol. 2013 Jan;40(1):73-81. doi: 10.1111/jcpe.12016. Epub 2012 Nov 8.PMID: 23137193

Kuperman S, Efraty R, Arie I, et al. Int J Environ Res Public Health. 2020 Jul 6;17(13):4854. doi: 10.3390/ijerph17134854.PMID: 32640560

Arie I, Pal A, Buch-Dan G, et al. Medical Research Archives, [S.l.], v. 12, n. 5, may 2024. ISSN 2375-1924. 

Ganz J, Arie I, Ben-Zur T, et al. Stem Cells Transl Med. 2014 Mar;3(3):375-86. doi: 10.5966/sctm.2013-0074. Epub 2014 Jan 29.PMID: 2447707

Kent I, Jahansouz C, Ghuman A, et al. Eur Surg Res. 2021;62(1):32-39. doi: 10.1159/000514987. Epub 2021 Apr 26.PMID: 33902028

Circle-bg
Cytora bottom logo

MENU

Cytora’s patented platform technology is based on the discovery of a novel and unique stem cell population in the human oral mucosa (hOMSC), the origin of which is the embryonic nervous system. hOMSC are endowed with properties of neural crest, neural and mesenchymal stem cells. Cytora’s products are allogeneic, off-the-shelf, easily scalable, with a very competitive cost of goods (COG). The products were found to be safe and effective in early phase clinical trials in two indications: Diabetic Foot Ulcers (DFU) and Multiple System Atrophy (MSA).

Our products have high potential for treating complicated multifactorial diseases such as chronic and neurodegenerative diseases, incurable wounds and autoimmune diseases.

CONTACT US

© 2022 Cytora. All rights reserved.

bottom of page